Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL314282 | 0.69 | — | — | |
| SCHEMBL14660620 | 0.67 | HTR3A (0.37) | — | |
| SCHEMBL314963 | 0.66 | — | — | |
| SCHEMBL29850387 | 0.63 | DDB1 (0.38) | PDE4APDE4BPDE4CPDE4DDDB1 | |
| SCHEMBL20891224 | 0.63 | DDB1 (0.43) | PDE4APDE4BPDE4CPDE4DDDB1 | |
| SCHEMBL7358244 | 0.63 | MAPT (0.40) | — | |
| SCHEMBL30684650 | 0.63 | DDB1 (0.61) | PDE4APDE4BPDE4CPDE4DDDB1 | |
| SCHEMBL5607760 | 0.62 | — | — | |
| SCHEMBL22762375 | 0.61 | MAPK1 (0.40) | — | |
| SCHEMBL3290525 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138183-B2 | Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K | ASTRAZENECA AB (SE) | 2012-03-20 | — | — | US | disclosed |
| US-20100249131-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USED IN DISEASES LINKED TO MTOR KINASE AND/OR PI3K | ASTRAZENECA AB (SE) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249131-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USED IN DISEASES LINKED TO MTOR KINASE AND/OR PI3K | PIK3CA, MTOR, PIK3CD | PDE4A 2350/4885PDE4B 2324/4885PDE4C 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.